Stocktoria
Tarsus Pharmaceuticals, Inc. TARS
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-10-16
Tarsus Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $451.4M | $183.0M | $17.4M | $25.8M | $57.0M | $0 | — |
| R&D expense | $64.3M | $53.4M | $50.3M | $42.6M | $41.7M | $18.8M | $3.2M |
| SG&A expense | $427.3M | $237.3M | $108.7M | $44.9M | — | — | — |
| Operating income | -$71.0M | -$120.6M | -$143.2M | -$62.7M | -$12.2M | -$27.0M | -$4.3M |
| Interest expense | — | — | $3.3M | $2.2M | $0 | — | — |
| Income tax | $2.1M | $0 | $0 | -$4,000 | $55,000 | $1,000 | $1,000 |
| Net income | -$66.4M | -$115.6M | -$135.9M | -$62.1M | -$13.8M | -$26.8M | -$4.7M |
| EPS (diluted) | $-1.59 | $-3.07 | $-4.62 | $-2.52 | $-0.67 | $-4.32 | — |
| Operating cash flow | -$12.5M | -$83.0M | -$117.5M | -$49.0M | $3.7M | -$21.1M | -$3.7M |
| Free cash flow | -$22.3M | -$84.6M | -$119.0M | -$49.5M | $3.2M | -$21.6M | -$3.8M |
| Cash & equivalents | $183.6M | $94.8M | $224.9M | $71.7M | $171.3M | $168.1M | $58.0M |
| Inventory | $4.4M | $2.6M | $3.1M | $0 | — | — | — |
| Total assets | $562.2M | $377.0M | $265.5M | $227.9M | $178.9M | $172.0M | $58.3M |
| Total liabilities | $218.7M | $152.5M | $68.5M | $35.0M | $12.2M | $6.0M | $919,000 |
| Shareholders' equity | $343.4M | $224.5M | $197.0M | $192.9M | $166.7M | $166.0M | -$6.0M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +146.7% | +948.6% | -32.4% | -54.7% | — | — | — |
| Free cash flow growth | — | — | — | -1666.6% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.